Be the first person to write a business review for QuA Vodis Limited

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

QUATRx Pharmaceuticals hopes to capitalize on the bright ideas of others. The biopharmaceutical company acquires compounds in the pre-clinical stage from other companies and academic institutions and takes them through clinical studies then licensing them to pharma giants. The company focuses on developing new therapies for cardiovascular, endocrine, and metabolic conditions. Products in clinical trials include treatments for age-related hormone deficiencies in women and men as well as drugs for high cholesterol and the treatment of psoriasis. Hormos Medical, QUATRx's Finnish subsidiary, conducts most of its preclinical and discovery programs.

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), with operations in more than 50 countries, it helps drug and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its Innovex subsidiary is a contract sales organization providing sales personnel to promote approved products. An investment group led by founder and CEO Dennis Gillings owns the company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.